单位:[1]Laboratory of China-Japan Friendship Hospital, Sakura Garden East Street, Beijing 100029, People’s Republic of China[2]Department of Echocadiography, The First Hospital of JiLin University, 71 Xinmin Street, Changchun 132200, People’s Republic of China[3]Department of Pathology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, People’s Republic of China[4]School of Resources and Chemical Engineering, Sanming University, Sanming, Fujian, People’s Republic of China[5]Fujian Engineering Research Center for Advanced Fluorine-containing Materials, Sanming, Fujian, People’s Republic of China
IntroductionDermatomyositis (DM) is a rare autoimmune myopathy characterized by skin lesions, proximal muscle weakness and muscle inflammation. The pathogenesis of DM is unclear, and identification of reliable biomarkers for early diagnosis of DM is critical for design of a specific therapy for this disease.ObjectivesTo find and identify potential serum biomarkers in DM patients.MethodsWe performed an untargeted metabolomic approach using UHPLC-MS/MS. The blood serum metabolomic profiles of 26 DM patients and 26 healthy controls were collected. Multivariate analysis of the metabolomic profile was applied to differentiate DM patients and controls and to find potential biomarkers.ResultsA significantly disturbed metabolic profile of DM patients was observed. Pathway analysis showed that aminoacyl-tRNA biosynthesis, phenylalanine, tyrosine and tryptophan biosynthesis, and nitrogen metabolism are the most prominently altered pathways in DM. Receiver operating characteristic curve indicated that glutamine, methionine, isoleucine, tryptophan, glutamic acid, indole, protocatechuic acid, and phenylalanine were potential biomarkers for DM diagnosis in terms of both sensitivity and specificity.ConclusionsOur study provides new insight into underlying mechanisms of DM, and we suggest that we should pay more attention to these metabolic pathways in the prevention and treatment of DM.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81301801, 81430056]; Science and Technology Planning Project of Chaoyang District, Beijing [CYSF1835]; R&D Infrastructure and Facility Development Program of Fujian [2018H2002]; Industry University Research Project of Fujian [2018H6101]; National Health and Family Planning Commission of the People's Republic of China [W2015CAE016]
第一作者单位:[1]Laboratory of China-Japan Friendship Hospital, Sakura Garden East Street, Beijing 100029, People’s Republic of China
通讯作者:
通讯机构:[3]Department of Pathology, Institute of Systems Biomedicine, School of Basic Medical Sciences, Beijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, People’s Republic of China[4]School of Resources and Chemical Engineering, Sanming University, Sanming, Fujian, People’s Republic of China[5]Fujian Engineering Research Center for Advanced Fluorine-containing Materials, Sanming, Fujian, People’s Republic of China
推荐引用方式(GB/T 7714):
Zhang Tie,Xu Jing,Liu Yang,et al.Metabolomic profiling for identification of potential biomarkers in patients with dermatomyositis[J].METABOLOMICS.2019,15(5):doi:10.1007/s11306-019-1539-9.
APA:
Zhang, Tie,Xu, Jing,Liu, Yang&Liu, Jia.(2019).Metabolomic profiling for identification of potential biomarkers in patients with dermatomyositis.METABOLOMICS,15,(5)
MLA:
Zhang, Tie,et al."Metabolomic profiling for identification of potential biomarkers in patients with dermatomyositis".METABOLOMICS 15..5(2019)